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Objectives: Chronic idiopathic (or spontaneous) urticaria (CIU) is estimated to 
occur in 0.3% of the general population in Turkey. Although the burden of the dis-
ease is substantial for the payer, there has been no cost-analysis performed in our 
country. The purposes of this study are to determine the resources and costs related 
to the diagnosis and treatment of patients with CIU, and to estimate the annual eco-
nomic burden to the Social Security Institution (SGK). MethOds: Delphi technique 
was applied to determine the type and the amount of resources used in different 
stages of CIU defined as mild or moderate to severe based on physicians clinical 
assessment. The Delphi method solicits the opinion of an expert panel through a 
carefully designed questionnaire which in this case included questions on: epi-
demiology, diagnosis, treatment of symptoms and angioedema, adverse events, 
follow-up visits, hospital and emergency service admissions. The responses were 
analysed and discussed in a face to face meeting followed by consensus building 
steps. Unit of resources used for different CIU severity levels were determined from 
expert opinion. Unit costs of resources used in outpatient clinics were obtained 
from SGK’s Reimbursement Guideline-List of Procedure Fees Per Service. Results: 
Hospitalizations, emergency admissions, outpatient visits and treatments, are the 
key cost drivers in the management of CIU The annual cost per patient is calcu-
lated to be 725.36 Turkish Liras (TL) for mild CIU, 1.322,61 TL for moderate CIU and 
2,478.75 TL for severe CIU. The total annual cost of CIU to SGK is estimated to be 262 
million TL in 2014. cOnclusiOns: This is the first study that aims to estimate the 
resource utilisation and cost burden of CIU in Turkey by using the Delphi technique. 
Cost effective treatment of CIU is an unmet need given the heavy burden to SGK 
identified by the Delphi Panel.
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Objectives: Treatment delays in patients with wAMD and DME are very impor-
tant since they are associated with disease progression. This is the first study in 
Greece to highlight patient’s access delays’ to treatment and to estimate the burden 
of diseases in Greece. MethOds: An expert panel with 11 ophthalmologists was 
convened. The experts came from six out of seven Regional Health Authorities, 
covering geographically the largest part of the country. A 13-page questionnaire 
was developed and validated. The Delphi technique was used to collect data on 
resource use and disease management, patient access delays, and indirect costs. 
Unit costs were retrieved from NHS sources and the analysis was conducted from 
the societal perspective, including direct costs incurred by patients, their families 
and the health care system, and indirect costs, of productivity losses. Results: 
Total cost of managing wAMD during the first year of treatment was estimated at 
€ 20,660,32.8% of which consisted of direct costs (drug acquisition and administra-
tion, follow-up, lab and imaging tests), and 67.2% of which included non-medical 
and indirect costs (caregivers). Direct medical cost per DME patient for the first year 
of treatment was estimated at € 6,066, while the non-medical and indirect costs were 
estimated at € 12,271, resulting in a total cost of € 18,337 per patient per year. 91% of 
the experts agreed that there are significant delays in patient access to specific treat-
ments (average 20 days); all agreed (100%) that these delays lead to faster disease 
progression, and a strong majority (> 80%) supported that they lead to deterioration 
of patients’ QoL. cOnclusiOns: There are significant costs associated with the 
management of wAMD and DME in Greece, 70% of which is incurred by patients and 
their families. Administrative procedures leading to patient access delays should be 
minimized in order to avoid disease progression and associated costs.
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Objectives: Burn care has rapidly improved in the past decades. However, health 
care innovations can be expensive, demanding careful choices on their implementa-
tion. Obtaining knowledge on the extent of the costs of burn injuries is an essential 
first step for economic evaluations within burn care. The objective of this study was 
to determine the economic burden of patients with burns admitted to a burn center 
and to identify important cost categories until three months post-burn. MethOds: 
A prospective cohort study was conducted in the burn center of Maasstad Hospital 
Rotterdam, the Netherlands, including all patients with acute burn related injuries 
from August 2012 until July 2013. Total costs were calculated from a societal perspec-
tive, until three months post injury. Subgroup analyses were performed to examine 
whether the mean total costs per patient differed by age, etiology or percentage 
total body surface area (TBSA) burned. Results: In our population, with a mean 
burn size of 8%, mean total costs were € 24,246 per patient varying from € 11,498 to 
€ 71,756. Most important cost categories were burn center days, surgical interven-
tions and work absence. Flame burns were significantly more costly than other types 
of burns, adult patients were significantly more costly than children and adolescents 
decreased with VI severity (the adjusted difference in LP between participants with 
mild and moderate/severe VI= S$0.22K, P= 0.3846). cOnclusiOns: Visual impair-
ment poses substantial economic burden on individuals and families in Singapore. 
The economic burden of VI is mainly medical costs. Self-reported health problems 
seem to be better predictors of costs of VI than clinical measures.
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Objectives: Burn care is traditionally considered expensive care. However, detailed 
information about the costs of burn care is scarce, despite the increased need for this 
information and the enhanced focus on health care cost control. In this study, eco-
nomic literature on burn care was systematically reviewed to examine the problem 
of burn-related costs. MethOds: Cost or economic evaluation studies on burn care 
that had been published in international peer-reviewed journals from 1950-2012 
were identified. The methodology of these articles was critically appraised by two 
reviewers, and cost results were extracted. Results: A total of 156 studies met the 
inclusion criteria. Nearly all of the studies were cost studies (n= 153) with a health 
care perspective (n= 139) from high income countries (n= 127). Hospital charges were 
often used as a proxy for costs (n= 44). Three studies were cost-effectiveness analy-
ses. The mean total health care cost per burn patient in high-income countries was 
$88,218 (range $704- $717,306, median $44,024). cOnclusiOns: A wide variety of 
methodological approaches and cost prices was found. We recommend that cost 
studies and economic evaluations employ a standard approach to improve the 
quality and harmonization of economic evaluation studies, optimize comparability 
and improve insight into burn care costs and efficiency.
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Objectives: To appraise the literature referred to direct and indirect costs of pso-
riasis in Europe. MethOds: A systematic review of the literature was performed. 
Electronic databases [MedLine/PubMed, Scopus, Cochrane Library, ISI Wok, MEDES, 
IBECS, CSIC] and Google Scholar were searched to identify publications referred 
to direct and indirect costs of psoriasis in Europe. Bibliographic references were 
hand searched. European studies published in English or Spanish until October 
2013 were selected. Economic evaluations of specific drugs and of preventive or 
diagnostic interventions were excluded. Costs were updated to € , 2013. Results: 
12 studies were reviewed (4 German, 2 Swedish, 2 Italian, 1 Dutch, 1 
French, 1 English and 1 Spanish). From the social perspective, the mean 
annual cost of psoriasis in Europe was heterogeneous and varied between 
€ 1,340.25 (Spain) and € 8,253.74 (Italy), mainly due to differences of study 
sample characteristics, methodology used and national health system 
features. The highest proportion (68%-82.5%) of total costs was attribut-
able to direct costs (hospitalizations, medications and laboratory tests). 
The annual total cost of severe psoriasis was, at least, 2.5 fold superior to the costs 
of mild disease, mostly because of a more frequent use of hospital resources and 
loss of productivity. Out-of-pocket expenditure ranged from € 480.67 to € 797.00, 
being mostly explained by the use of dermatological products (OTC) (29%-59.7%) 
and alternative therapies (balnerotherapies) (24%-49%). The initiation of biologic 
therapies implied reductions of up to 76% on the length of hospital stay and up to 
98% hospital admissions, contributing to a decline of inpatient cost [€ 2,357.30 (SD: 
722.29) vs. € 564.19 (SD: 257.62); p= 0.005; UK]. cOnclusiOns: Costs results vary 
across European countries. Severe psoriasis is a costly disease. The use of biologic 
agents may contribute to a more efficient management of severe psoriasis due to 
a more steady control of symptoms that improve clinical outcomes and decrease 
the needs for hospital care and inpatient cost.
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Objectives: To provide a literature overview on the costs of diabetic complications 
focused on the economic burden of Diabetic Macular Edema (DME) and associated 
vision loss and blindness. MethOds: Literature searches in PubMed (including 
Medline) and Embase were conducted to identify economic data related to diabetic 
retinopathy, macular edema, blindness and low vision. Posterior filters included 
year of publication (from 2000 to May 2014), country (Canada, USA or Europe) and 
English language. Relevant full text articles were reviewed and major findings sum-
marized. Results: A total of 468 citations from 5 different searches were retrieved 
and 16 studies fulfilled the criteria to be summarized in this review. Microvascular 
diabetic complications were found to be frequent and led to a 70% increase in 
direct costs compared to patients with no complications. When microvascular and 
macrovascular complications were given together, management costs increased 
by up to 250%. Eye disease was associated with a 2,5 ratio of extra cost compared 
to diabetic patients without complications, with DME incurring in twice to 3 times 
higher costs related to Diabetic Retinopathy. Direct costs of DME accounted for 
65-80% of total costs, with 73% of those being associated to hospital expenditure. 
Data on the economic burden of visual impairment and blindness were limited: 
vision loss had an annual per capita financial cost of $19.370 in Canada (2007); 
including the value of lost wellbeing, the annual cost of vision loss was $33.704 
per patient. cOnclusiOns: DME appears to be a costly complication of diabetes. 
Progression to visual impairment and blindness can lead to high economic and 
social burden.
